Laboratorios Farmaceuticos ROVI, Proteros biostructures, Bionor Pharma

• ROVI will be responsible for the promotion and distribution of Neparvis in Spain.
• The agreement allows the partners to begin marketing of Neparvis in the first quarter of next year.

Proteros biostructures and Merck Sharp & Dohme Corp have entered a research agreement to develop small molecule compounds against a number of cancer types.

• Proteros will receive an upfront payment and research funding of up to $167m, which is inclusive of development, regulatory and commercial milestone payments.
• The agreement enables the partners to develop small molecule compounds against epigenetic target.

Pharming Group plans to raise gross proceeds of approximately $17.2m in net proceeds through the private placement of 8.5% redeemable convertible bonds.

• The company plans to use the funds to acquire all North American commercialisation rights to its own product Ruconest from Valeant Pharma.

Bionor Pharma plans to raise gross proceeds of $17.4m through private placement of its shares. The offering is expected to be completed by December.

• Arctic Securtities, DNB Markets and Sparebank 1 Markets are acting as the underwriters for the offering.

Recursion Pharma has raised additional $2.15m in a series A venture financing round led by Felicis Ventures and other investors.

• The company plans to invest the funds to develop its drug and target discovery technology in sectors such as ageing, inflammation, infectious diseases, diagnostics and oncology.

Laboratorios farmaceuticos rovi, proteros biostructures, bionor pharma